PT Kalbe Farma Tbk (KLBF) Q3 2025 earnings summary

Executive summary

• Net sales reached IDR 25.99 trillion for the nine months ended September 2025, up 7.2% year-over-year, with net profit growing 10.6% to IDR 2.63 trillion.

• Growth was driven by volume increases, margin improvements, and ongoing marketing investments to sustain future expansion.

• Strategic collaborations and investments in biologics, radiopharmaceuticals, and medical devices supported portfolio expansion.

• Gross profit rose to IDR 10.56 trillion, with gross margin improving to 40.6%.

• Total assets stood at IDR 30.10 trillion, and total equity at IDR 24.80 trillion as of September 30, 2025.

Financial highlights

• Operating profit increased to IDR 3.48 trillion, and net income attributable to owners grew 10.6% to IDR 2.63 trillion.

• Basic EPS rose 12.6% to 57.79.

• Cash and cash equivalents at period end were IDR 4.05 trillion, down year-to-date.

• Total liabilities increased to IDR 5.30 trillion from IDR 4.84 trillion at year-end 2024.

• Operating cash flow for the period was IDR 2.18 trillion, compared to IDR 3.53 trillion in the prior year.

Outlook and guidance

• Full-year 2025 sales growth is projected at 6–8%, with net profit growth also targeted at 6–8%.

• Capex for 2025 is set at IDR 1.0 trillion, focused on production, distribution, and network expansion.

• Dividend payout ratio is expected to remain between 50–60%.

• Management continues to monitor macroeconomic and political risks, especially in Myanmar, and expects ongoing volatility.

• The company maintains a focus on operational efficiency and capital discipline.